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Do we need new trials of procalcitonin-
guided antibiotic therapy? A response
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See related Commentary by Lisboa et al., https://ccforum.biomedcentral.com/articles/10.1186/s13054-018-1948-6
Antibiotic treatment needs to be short, appropriate
(focused on the right pathogen), and adequate (at the
right dosage). And still, many physicians treat patients
for too long. A recent meta-analysis on procalcitonin
(PCT)-guided antibiotic treatment in acute respiratory
infections [1] showed that antibiotics could be shortened
form 8.1 to 5.7 days. The key question is, why do physi-
cians treat for so long? The answer may be fear! Fear of
undertreatment.
We read with great interest the commentary by Lisboa
and colleagues in Critical Care [2] in which they ques-
tion the clinical utility of this meta-analysis [1]. They
concluded that populations in previous trials were not
receiving best care, had less adherence to PCT algo-
rithms, and lacked information on specific conditions
and populations. As authors of the largest study in-
cluded in this meta-analysis, the Stop Antibiotics on
Procalcitonin guidance Study (SAPS) [3], we want to
respond. SAPS was a pragmatic randomized controlled
trial in the Netherlands with 1546 adult ICU patients
with antibiotics for a presumed infection. We demon-
strated a highly significant reduction in initial antibiotic
duration (5.0 vs 7.0 days). The median duration of anti-
biotic treatment (DOT) in the control group of the total
population was 7 days (interquartile range (IQR) 4–11
days). Of these patients, 65% had a presumed pulmonary
infection. Dutch national guidelines recommend an anti-
biotic duration for moderate-severe community-acquired
pneumonia (CAP) of 5 days [4]. No such advice exists for
severe pneumonia admitted to the ICU. The median DOT
in the control group in CAP was 7 days (IQR 4–10 days), 6
days (IQR 4–10 days) in hospital-acquired pneumonia and
7 days (IQR 5–11 days) in ventilator-associated pneumonia.
The wide IQR suggests that physicians are reluctant to trust
guidelines and prefer to prolong antibiotic treatment if they
believe it is necessary. Moreover, physicians may perform
even better in clinical trials, because they know they are be-
ing watched, commonly referred to as the “Hawthorne ef-
fect”. In SAPS the patients were already on antibiotics.
When a PCT-stopping criterion was reached antibiotics
were stopped in 53% of the patients within 48 h. It was a
stopping advice. Sensitivity and specificity are not high
enough to withhold antibiotics on PCT alone. And indeed,
PCT is no holy grail. Like other biomarkers, there are nu-
merous non-infectious inflammatory processes, i.e., trauma,
surgery, and acute kidney injury, in which PCT can be ele-
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